PMV Pharmaceuticals (PMVP) Stock Price, News & Analysis

Company Overview

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

Key Stats

• Today's Range: $1.36 to $1.40
• 50-Day Range: $1.35 to $1.69
• 52-Week Range: $1.32 to $2.26
• Volume: 59,171 shs
• Average Volume: 129,477 shs
• Market Capitalization: $70.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.50
• Consensus Rating: Buy

PMV Pharmaceuticals Stock Analysis - MarketRank™

PMV Pharmaceuticals scored higher than 45% of companies evaluated by MarketBeat, and ranked 680th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

PMV Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

PMV Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for PMV Pharmaceuticals are expected to decrease in the coming year, from ($1.06) to ($1.55) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of PMV Pharmaceuticals is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of PMV Pharmaceuticals is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

PMV Pharmaceuticals has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.06% of the float of PMV Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

PMV Pharmaceuticals has a short interest ratio ("days to cover") of 6.9.

Change versus previous month

Short interest in PMV Pharmaceuticals has recently increased by 2.29%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PMV Pharmaceuticals does not currently pay a dividend.

Dividend Growth

PMV Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.06% of the float of PMV Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

PMV Pharmaceuticals has a short interest ratio ("days to cover") of 6.9.

Change versus previous month

Short interest in PMV Pharmaceuticals has recently increased by 2.29%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for PMVP on MarketBeat in the last 30 days.

MarketBeat Follows

4 people have added PMV Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, PMV Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.60% of the stock of PMV Pharmaceuticals is held by insiders.

Percentage Held by Institutions

90.20% of the stock of PMV Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PMVP Stock Analysis - Frequently Asked Questions

How have PMVP shares performed this year?

PMV Pharmaceuticals' stock was trading at $1.51 at the beginning of the year. Since then, PMVP shares have decreased by 9.3% and is now trading at $1.37.
View the best growth stocks for 2025 here.

How were PMV Pharmaceuticals' earnings last quarter?

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) issued its quarterly earnings data on Thursday, November, 7th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by $0.02.

When did PMV Pharmaceuticals IPO?

PMV Pharmaceuticals (PMVP) raised $126 million in an initial public offering on Friday, September 25th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, BofA Securities, Cowen and Evercore ISI served as the underwriters for the IPO.

Who are PMV Pharmaceuticals' major shareholders?

PMV Pharmaceuticals' top institutional shareholders include Assenagon Asset Management S.A. (0.30%). Insiders that own company stock include Deepika Jalota, Michael Carulli and Orbimed Advisors Llc.
View institutional ownership trends.

How do I buy shares of PMV Pharmaceuticals?

Shares of PMVP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of PMV Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PMV Pharmaceuticals investors own include Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), NIO (NIO), Meta Platforms (META), Plug Power (PLUG), Aptose Biosciences (APTO) and Clean Energy Fuels (CLNE).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 1/20/2025
• Next Earnings (Estimated): 3/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PMVP
• CUSIP: N/A
• CIK: 1699382
• Web: www.pmvpharma.com
• Phone: 609-642-6670
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $5.50
• High Stock Price Target: $6.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +301.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-68,960,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -24.20%
• Return on Assets: -21.67%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.98
• Quick Ratio: 13.98

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.41 per share
• Price / Book: 0.31

Miscellaneous

• Outstanding Shares: 51,750,000
• Free Float: 47,814,000
• Market Cap: $70.90 million
• Optionable: Optionable
• Beta: 1.46